Alzheimer’s Disease Diagnostics Market By Type (Early Onset Alzheimer’s, Late-Onset Alzheimer’s, Familial Alzheimer’s Disease, and Others), By Diagnostic Tests (Genetic Testing, Neurological Exam, Mini-Mental State Exam (MMSE), Brain Imaging, and Others), By End User (Clinic, Hospital, Diagnostic Centre, and Others), and Geography

Alzheimer’s Disease Diagnostics Market size was valued at USD 4,987.1 million in 2023 and is poised to grow at a CAGR of 9.7% from 2024 to 2030. Alzheimer’s disease is a progressive brain disorder characterized by memory loss, impaired thinking, and changes in behavior. It leads to brain cell death and abnormal protein deposits. While there’s no cure, medications can manage symptoms, and support programs are available for patients and caregivers. Early detection is crucial. The increasing incidence of chronic conditions, including dementia, underscores the urgency of early diagnosis. As more people are affected by these diseases, timely identification becomes crucial for effective management and intervention. By detecting symptoms early, healthcare providers can implement targeted strategies to improve patients’ quality of life and potentially slow disease progression.

Furthermore, investments in identifying specific biomarkers have led to personalized medicine, where treatments are tailored to individual needs. For instance, the Brain-Derived Tau (BD-tau) biomarker shows promise in Alzheimer’s diagnosis. It surpasses existing blood tests, specifically targeting Alzheimer ’s-related neurodegeneration. BD-tau also aligns with cerebrospinal fluid biomarkers. However, regulatory challenges significantly affect the Alzheimer’s disease diagnostic market. Researchers and clinicians grapple with standardizing diagnostic tools, ensuring reliability, navigating ethical considerations, and achieving widespread access to biomarker-based diagnostics while managing costs remains pivotal for equitable healthcare delivery.  

Alzheimer’s Disease Diagnostics Market Key Developments:

In March 1, 2022, Quanterix, a life sciences company announced collaboration with Eli Lilly and Company, a pharmaceutical company.

• The collaboration agreement focuses on the diagnosis, monitoring, and treatment of Alzheimer's disease.
• The collaboration gives Eli Lilly and Company access to Quanterix's Simoa technology that is known for its ability to detect biomarkers at very low concentrations.